Recon: Lilly acquires Protomer in deal worth up to $1B; Some private insurers will refuse to cover Aduhelm
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy